• About us
• Contact

Advertisement

Organisation › Details

Hema.to GmbH

hema.to is an easy-to-use software for clinical decision support for blood cancer from cytometry data using AI. hema.to makes the diagnostic workflow both faster and better, helping both diagnosticians as well as patients. hema.to is a CE-IVD, FDA registered and already in routine use by leading hematology laboratories. Founded in 2021, hema.to’s mission is to make clinical analysis of cytometry data completely objective, to enable doctors to personalize treatment to their patient’s unique immune system. *

 

	Start	2021-10-19 established
	Industry	single cell analysis
	Person	Miermans, Karsten (Hema.to 202306 CEO + Co-Founder)
	Region	München (Munich)
	Country	Germany
	Street	22 Ainmillerstr.
	City	80801 München
		Address record changed: 2023-07-03
Basic data	Employees	n. a.
		* Document for »About Section«: High-Tech Gründerfonds Management GmbH. (6/26/23). "Press Release: Hema.to Raises €3.6M to Bring Precision Diagnostics to Immune Medicine Using AI-assisted Analysis of Single-cell Blood Data".
		Record changed: 2025-07-06

Advertisement

More documents for Hema.to GmbH

• [1] High-Tech Gründerfonds Management GmbH. (6/26/23). "Press Release: Hema.to Raises €3.6M to Bring Precision Diagnostics to Immune Medicine Using AI-assisted Analysis of Single-cell Blood Data"....

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2025. Made in Germany.